NEW YORK CITY, NY / ACCESS Newswire / September 3, 2025 / iRobot Corporation (NASDAQ:IRBT)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. In August 2022, iRobot entered into a merger agreement with Amazon.com, Inc. ("Amazon") pursuant to which Amazon would acquire iRobot for $61 per share in an all-cash transaction. However, in January 2024, Amazon and iRobot announced that they had mutually agreed to terminate the Amazon Acquisition, citing regulatory concerns. In the wake of the Amazon Acquisition’s termination, iRobot touted that it would be implementing an operational restructuring plan (the "Restructuring Plan"). The Restructuring Plan, according to the Company, would "enable [it] to chart a new strategic path for sustainable value creation."
Allegedly, however, the Company made materially false and misleading statements or failed to disclose that (1) iRobot overstated the extent to which the Restructuring Plan would help the Company maintain stability after the termination of the Amazon acquisition; (2) as a result, it was unlikely that iRobot would be able to profitably operate as a standalone company; (3) thus, there was significant doubt regarding the Company’s ability to continue as a going concern; and (4) as a result, the Company’s public statements were materially false and misleading.
If you are an IRBT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Centene Corporation (NYSE:CNC)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. The Company provided investors with material information concerning Centene’s expected revenue guidance and adjusted diluted EPS for fiscal year 2025. These statements included, among other things, the Company’s enrollment and morbidity rates, as well as strong retention rates in Centene’s Medicare business.
Allegedly, however, the Company provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the truth of the Company’s enrollment and morbidity rates.
If you are a CNC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. The Company provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. The Company’s statements included Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration.
The Company allegedly provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.
If you are a CAPR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Neogen Corporation (NASDAQ:NEOG)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. In December 2021, it was announced that Neogen would merge with the Food Safety Division of the 3M Company. The deal closed in September 2022. Upon closing, Neogen commenced what would become a lengthy and complicated integration process.
On January 25, 2025, the Company revealed, among other things, that GAAP net income in the second quarter was significantly negative due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition. In addition, the Company revealed that, as of November 30, 2024, Neogen had material weaknesses in its internal control over financial reporting. On this news, the price of the Company’s common stock declined 5% to close at $12.36 per share. Allegedly, the Company misrepresented the status of the 3M integration and failed to disclose the negative impact of integration issues on the financial health of Neogen.
If you are a NEOG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
ATTORNEY ADVERTISING.© 2025 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: jlifshitz@lifshitzlaw.com
SOURCE: Lifshitz Law Firm
View the original press release on ACCESS Newswire
COMTEX_468525827/2457/2025-09-03T15:00:04